{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T20:34:36Z","timestamp":1791232476829,"version":"4.1.0"},"reference-count":42,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2010,10,1]],"date-time":"2010-10-01T00:00:00Z","timestamp":1285891200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2010,10]]},"DOI":"10.1016\/j.ygyno.2010.05.033","type":"journal-article","created":{"date-parts":[[2010,7,3]],"date-time":"2010-07-03T08:34:40Z","timestamp":1278146080000},"page":"32-37","source":"Crossref","is-referenced-by-count":188,"title":["A Phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancer"],"prefix":"10.1016","volume":"119","clinical-trial-number":[{"clinical-trial-number":"nct00281632","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Michael","family":"Friedlander","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth C.","family":"Hancock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danny","family":"Rischin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark J.","family":"Messing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claude A.","family":"Stringer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gemma M.","family":"Matthys","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey P.","family":"Hodge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanne J.","family":"Lager","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2010.05.033_bib1","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3322\/CA.2007.0010","article-title":"Cancer statistics, 2008","volume":"58","author":"Jemal","year":"2008","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ygyno.2010.05.033_bib2","doi-asserted-by":"crossref","first-page":"2435","DOI":"10.1016\/S0959-8049(02)00495-1","article-title":"Moderate progress for ovarian cancer in the last 20years: prolongation of survival, but no improvement in the cure rate","volume":"38","author":"Engel","year":"2002","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ygyno.2010.05.033_bib3","doi-asserted-by":"crossref","first-page":"3084","DOI":"10.1200\/JCO.2000.18.17.3084","article-title":"Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer","volume":"18","author":"Neijt","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2010.05.033_bib4","doi-asserted-by":"crossref","first-page":"3194","DOI":"10.1200\/JCO.2003.02.153","article-title":"Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study","volume":"21","author":"Ozols","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2010.05.033_bib5","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1200\/JCO.20.5.1248","article-title":"Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis","volume":"20","author":"Bristow","year":"2002","journal-title":"J Clin Oncol"},{"issue":"suppl 1","key":"10.1016\/j.ygyno.2010.05.033_bib6","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1023\/A:1008355317514","article-title":"First line chemotherapy with carboplatin plus paclitaxel in advanced ovarian cancer\u2014a new standard of care?","volume":"10","author":"du Bois","year":"1999","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ygyno.2010.05.033_bib7","first-page":"766","article-title":"Ovarian cancer. Clinical practice guidelines in oncology","volume":"6","author":"Morgan","year":"2008","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.ygyno.2010.05.033_bib8","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1038\/ncponc0637","article-title":"Ovarian cancer: a focus on management of recurrent disease","volume":"3","author":"Herzog","year":"2006","journal-title":"Nat Clin Pract Oncol"},{"key":"10.1016\/j.ygyno.2010.05.033_bib9","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.ygyno.2008.08.033","article-title":"Cytoreductive surgery for recurrent ovarian cancer: a meta-analysis","volume":"112","author":"Bristow","year":"2009","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2010.05.033_bib10","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1200\/JCO.2005.01.2757","article-title":"Comparison of CA-125 and standard definitions of progression of ovarian cancer in the intergroup trial of cisplatin and paclitaxel versus cisplatin and cyclophosphamide","volume":"24","author":"Rustin","year":"2006","journal-title":"J Clin Oncol"},{"issue":"suppl 2","key":"10.1016\/j.ygyno.2010.05.033_bib11","doi-asserted-by":"crossref","first-page":"ii14","DOI":"10.1093\/annonc\/mdn073","article-title":"Epithelial ovarian carcinoma: ESMO clinical recommendations for diagnosis, treatment and follow-up","volume":"19","author":"Aebi","year":"2008","journal-title":"Ann Oncol"},{"issue":"10 suppl","key":"10.1016\/j.ygyno.2010.05.033_bib12","doi-asserted-by":"crossref","first-page":"187s","DOI":"10.1200\/JCO.2003.01.223","article-title":"Use of CA-125 to assess response to new agents in ovarian cancer trials","volume":"21","author":"Rustin","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2010.05.033_bib13","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1093\/jnci\/92.18.1534","article-title":"Re: new guidelines to evaluate the response to treatment in solid tumors [ovarian cancer]. Gynecologic Cancer Intergroup","volume":"92","author":"Vergote","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ygyno.2010.05.033_bib14","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2009.27.18_suppl.1","article-title":"A randomized trial in ovarian cancer (OC) of early treatment of relapse based on CA125 level alone versus delayed treatment based on conventional clinical indicators (MRC OV05\/EORTC 55955 trials)","volume":"27","author":"Rustin","year":"2009","journal-title":"J Clin Oncol"},{"issue":"suppl 5","key":"10.1016\/j.ygyno.2010.05.033_bib15","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1634\/theoncologist.7-suppl_5-20","article-title":"Relapsed ovarian cancer: challenges and management strategies for a chronic disease","volume":"7","author":"Armstrong","year":"2002","journal-title":"Oncologist"},{"key":"10.1016\/j.ygyno.2010.05.033_bib16","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1177\/106689690501300202","article-title":"Correlation of epidermal growth factor receptor expression with tumor microdensity vessels and with vascular endothelial growth factor expression in ovarian carcinoma","volume":"13","author":"Raspollini","year":"2005","journal-title":"Int J Surg Pathol"},{"key":"10.1016\/j.ygyno.2010.05.033_bib17","first-page":"3193","article-title":"Preoperative serum vascular endothelial growth factor levels: significance in ovarian cancer","volume":"8","author":"Cooper","year":"2002","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ygyno.2010.05.033_bib18","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1038\/bjc.1997.537","article-title":"Expression of vascular endothelial growth factor (VEGF) in epithelial ovarian neoplasms: correlation with clinicopathology and patient survival, and analysis of serum VEGF levels","volume":"76","author":"Yamamoto","year":"1997","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ygyno.2010.05.033_bib19","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1006\/gyno.1999.5418","article-title":"Serum vascular endothelial growth factor in epithelial ovarian neoplasms: correlation with patient survival","volume":"74","author":"Chen","year":"1999","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2010.05.033_bib20","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1016\/j.ejca.2007.03.007","article-title":"Quantification of angiogenesis by the Chalkley method and its prognostic significance in epithelial ovarian cancer","volume":"43","author":"Suhonen","year":"2007","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ygyno.2010.05.033_bib21","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2007.25.18_suppl.9043","article-title":"Open-label safety and efficacy pilot trial of intraperitoneal bevacizumab as palliative treatment in refractory malignant ascites","volume":"25","author":"El-Shami","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2010.05.033_bib22","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1016\/S0002-9440(10)65669-6","article-title":"Role of vascular endothelial growth factor in ovarian cancer: inhibition of ascites formation by immunoneutralization","volume":"153","author":"Mesiano","year":"1998","journal-title":"Am J Pathol"},{"key":"10.1016\/j.ygyno.2010.05.033_bib23","unstructured":"U.S. Department of Health and Human Services Food & Drug Administration. Pazopanib [approval notice], published 2009. (http:\/\/www.fda.gov\/AboutFDA\/CentersOffices\/CDER\/ucm187509.htm)."},{"key":"10.1016\/j.ygyno.2010.05.033_bib24","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s11912-007-0007-2","article-title":"Pazopanib: a novel multitargeted tyrosine kinase inhibitor","volume":"9","author":"Sonpavde","year":"2007","journal-title":"Curr Oncol Rep"},{"key":"10.1016\/j.ygyno.2010.05.033_bib25","doi-asserted-by":"crossref","first-page":"4220","DOI":"10.1158\/1078-0432.CCR-08-2740","article-title":"Phase I trial of pazopanib in patients with advanced cancer","volume":"15","author":"Hurwitz","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ygyno.2010.05.033_bib26","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1002\/sim.4780110703","article-title":"Planned versus attained design in phase II clinical trials","volume":"11","author":"Green","year":"1992","journal-title":"Stat Med"},{"key":"10.1016\/j.ygyno.2010.05.033_bib27","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1093\/jnci\/djh081","article-title":"Re: New guidelines to evaluate the response to treatment in solid tumors (ovarian cancer)","volume":"96","author":"Rustin","year":"2004","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ygyno.2010.05.033_bib28","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada","volume":"92","author":"Therasse","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ygyno.2010.05.033_bib29","unstructured":"Cancer Therapy Evaluation Program. Common Terminology Criteria for Adverse Events v3.0 (CTCAE), published August 2006. (http:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/docs\/ctcaev3.pdf)."},{"key":"10.1016\/j.ygyno.2010.05.033_bib30","doi-asserted-by":"crossref","first-page":"5165","DOI":"10.1200\/JCO.2007.11.5345","article-title":"Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study","volume":"25","author":"Burger","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2010.05.033_bib31","doi-asserted-by":"crossref","first-page":"5180","DOI":"10.1200\/JCO.2007.12.0782","article-title":"Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer","volume":"25","author":"Cannistra","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2010.05.033_bib32","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1200\/JCO.2007.12.1939","article-title":"Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia","volume":"26","author":"Garcia","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2010.05.033_bib33","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ygyno.2008.02.009","article-title":"Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer: a trial of the Chicago, PMH, and California Phase II Consortia","volume":"110","author":"Nimeiri","year":"2008","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2010.05.033_bib34","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa060655","article-title":"Sorafenib in advanced clear-cell renal-cell carcinoma","volume":"356","author":"Escudier","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ygyno.2010.05.033_bib35","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJMoa065044","article-title":"Sunitinib versus interferon alfa in metastatic renal-cell carcinoma","volume":"356","author":"Motzer","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ygyno.2010.05.033_bib36","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2009.27.18_suppl.lba5509","article-title":"A randomized, phase III study of carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in relapsed platinum-sensitive ovarian cancer (OC): CALYPSO study of the Gynecologic Cancer Intergroup (GCIG)","volume":"27","author":"Pujade-Lauraine","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2010.05.033_bib37","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1002\/cncr.23374","article-title":"Lack of reliability of CA125 response criteria with anti-VEGF molecularly targeted therapy","volume":"112","author":"Azad","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2010.05.033_bib38","doi-asserted-by":"crossref","first-page":"2832","DOI":"10.1002\/cncr.23893","article-title":"Lack of reliability of CA125 response criteria with anti-VEGF molecularly targeted therapy [letter]","volume":"113","author":"Markman","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2010.05.033_bib39","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1016\/S0140-6736(07)61904-7","article-title":"Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial","volume":"370","author":"Escudier","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.ygyno.2010.05.033_bib40","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa032691","article-title":"Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer","volume":"350","author":"Hurwitz","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ygyno.2010.05.033_bib41","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa061884","article-title":"Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer","volume":"355","author":"Sandler","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ygyno.2010.05.033_bib42","doi-asserted-by":"crossref","first-page":"5601","DOI":"10.1200\/JCO.2009.23.2777","article-title":"Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer","volume":"27","author":"Matulonis","year":"2009","journal-title":"J Clin Oncol"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825810004257?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825810004257?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,6,6]],"date-time":"2020-06-06T13:26:57Z","timestamp":1591450017000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825810004257"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,10]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010,10]]}},"alternative-id":["S0090825810004257"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2010.05.033","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2010,10]]}}}